XML 138 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2023
Disclosure Text Block Supplement [Abstract]  
Schedule of Inventories

Inventories primarily relate to ENTADFI® product and consisted of the following as of December 31, 2023 and 2022:

  

December 31,
2023

  

December 31,
2022

Raw materials

  

$

139,208

  

$

—

Work-in-process

  

 

194,805

  

 

—

Finished goods

  

 

30,039

  

 

—

Total

  

$

364,052

  

$

—
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following as of December 31, 2023 and 2022:

  

December 31,
2023

  

December 31,
2022

Prepaid insurance

  

$

122,004

  

$

148,789

Prepaid regulatory fees

  

 

312,551

  

 

—

Prepaid research and development

  

 

89,195

  

 

231,981

Prepaid professional fees

  

 

70,708

  

 

—

Prepaid other

  

 

175,695

  

 

88,462

Total

  

$

770,153

  

$

469,232
Schedule of Intangible Assets

Intangible assets, which were recorded during the year ended December 31, 2023 in connection with the ENTADFI and Proteomedix acquisitions (see Note 5), is comprised of customer relationships, product rights for developed technology, and a trade name, and consisted of the following as of December 31, 2023:

  

Cost

  

Impairment

  

Effect of
Currency
Translation

  

Balance

Cost basis:

  

 

    

 

  

 

  

 

    

 

  

Trade name

  

$

9,018,000

  

$

—

 

  

$

294,739

  

$

9,312,739

Product rights for developed technology

  

 

28,447,771

  

 

(14,610,128

)

  

 

344,514

  

 

14,182,157

Customer relationships

  

 

1,891,000

  

 

—

 

  

 

61,803

  

 

1,952,803

Total

  

$

39,356,771

  

$

(14,610,128

)

  

$

701,056

  

$

25,447,699

 

Amortization

  

Balance

Accumulated amortization:

  

 

  

 

  

 

  

 

Trade name

  

$

—

 

  

$

—

 

Product rights for developed technology

  

 

(31,213

)

  

 

(31,213

)

Customer relationships

  

 

(5,599

)

  

 

(5,599

)

Total

  

$

(36,812

)

  

$

(36,812

)

Intangible assets, net

  

 

  

 

  

$

25,410,887

 
Schedule of Annual Amortization Expense

Future annual amortization expense related to the Company’s finite lived intangible assets is as follows as of December 31, 2023:

Years ending December 31,

  

 

  

2024

  

$

1,012,870

2025

  

 

1,326,837

2026

  

 

1,326,837

2027

  

 

1,326,837

2028

  

 

1,326,837

Thereafter

  

 

9,777,930

Total

  

$

16,098,148
Schedule of Goodwill

Goodwill was recorded during the year ended December 31, 2023, in connection with the Proteomedix acquisition (see Note 5), and consisted of the following as of December 31, 2023:

  

December 31,
2023

Balance as of December 31, 2022

  

$

—

PMX Transaction goodwill

  

 

53,914,055

Effect of currency translation

  

 

1,762,087

Balance as of December 31, 2023

  

$

55,676,142
Schedule of Accrued Expenses

Accrued expenses consisted of the following as of December 31, 2023 and 2022:

  

December 31,
2023

  

December 31,
2022

Accrued research and development

  

$

616,707

  

$

847,747

Accrued compensation

  

 

487,579

  

 

1,132,859

Accrued deferred offering costs

  

 

125,000

  

 

125,000

Accrued professional fees

  

 

550,415

  

 

—

Accrued implementation fees

  

 

93,787

  

 

—

Other accrued expenses

  

 

265,849

  

 

125,922

Accrued franchise taxes

  

 

60,530

  

 

177,600

Total

  

$

2,199,867

  

$

2,409,128